[G17-10] Nivolumab Squamous cell carcinoma of the head and neck - Addendum to A17-24
Last updated 17.11.2017
Commission awarded on 09.10.2017 by the Federal Joint Committee (G-BA).
If, in the course of the discussions on a commission of the G-BA, a need for further revision arises, IQWiG presents its report in the form of an addendum. The G-BA decides on the number of patients in the SHI target population.
|A18-40||Nivolumab (melanoma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)||Commission completed|
|A17-24||Nivolumab (squamous cell carcinoma of the head and neck) - Benefit assessment according to §35a Social Code Book V||Commission completed|